Trimeris' shareholder calls for sale of developer

Once one of the Triangle's most promising drug developers, Trimeris' largest shareholder is demanding that the company drop just about everything and focus on selling itself. "We are not in favor of strategic transactions other than those involving a sale of the business," wrote HealthCor in a letter dated Feb. 1. To make that point as clear as possible, HealthCor is asking for two seats on the board of directors. Trimeris' AIDS drug Fuzeon had been touted as a big seller, but disappointing sales punctured the optimism.

- read the article from the Charlotte News & Observer

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.